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Abstract 
 
Sickle cell disease (SCD) in general and sickle cell anemia in particular is a highly complex 
disorder both at the molecular and clinical levels. Although the molecular lesion is a single-point 
mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that 
constitute the various complications of the disease. Moreover, despite the fact that SCD is a 
chronic malady, its manifestations are both acute and chronic. The former include, among other 
things, the recurrent vaso-occlusive crises (its hallmark) and acute chest syndrome. The chronic 
complications include most commonly avascular necrosis and leg ulcers. Currently, survival of 
patients with SCD has improved dramatically thanks to newborn screening, antibiotic 
prophylaxis, better vaccine, safer blood transfusion and the use of hydroxyurea. It is the advent 
of these therapies that improved the survival. This improvement, however, introduced a third 
dimension of the disease: comorbidities that occur in aging people in the general population. 
There is concern that the gain in survival may be offset by the comorbidities. Thus it is the 
purpose of this review to identify the comorbidities in the elderly with SCD and differentiate 
them from the basis disease to implement proper therapies so that better survival could be 
maintained. 
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1. Introduction 
 
Survival of patients with sickle cell anemia (SS) has increased progressively since the 1970’s. 
Newborn screening, prophylactic antibiotics, newer vaccines, newer antibiotics, newer 
analgesics, safer blood transfusion, chelation therapy and hydroxyurea are some of the reasons 
for this change in longevity [1-4]. Patients with SS in their sixth, seventh or eighth decade have 
been described previously [5, 6]. In 1994 Platt et al [1] reported that the median age of survival 
for males with SS was 42 years and for females 48 years, Later the NIH reported that the median 
age for patients with SS is now in the late 50s approaching the early 60 years (Figure 1). Aging 
patients with SCD are at risk to develop comorbidities that often occur in the general population 
at large. The objective of this review is to promote understanding of the known co-morbidities 
associated with aging patients with SCD as they relate to appropriate management to improve the 
quality of life of older patients. 
1.1 Aging and SCD 
Old age in the general population usually refers to life expectancy of people beyond what is 
presumed to be the life expectancy of human beings. Specific definition of old age, however, 
varies greatly among countries, cultures, habitats, sociologists and gero-psychiatrists. Thus there 
are official definitions, popular definitions, sub-group definitions, etc. Gerontologists define sub-
group definitions in a number of ways [7, 8]. The sub-group definitions that seem to be in 
common use define young-old (65-74 years), middle- or older-old (75-84 years) and oldest old 
(≥ 85 years) [8]. These definitions may replace the definition of age by decades (Table 1) such as 
octogenarian (80 – 89 years) for example. 
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Treating older patients could be challenging. Patient-physician communication barriers may 
occur. Assessment of patients’ complaints is often difficult resulting in under- or overtreatment 
especially in patients who have irrational fears about therapeutic agents and/or cognitive 
changes. Providers may have difficulty to differentiate the signs and symptoms due to SCD from 
other comorbid conditions or side effects of medications to treat them [9-11]. Moreover, with 
aging physiologic changes occur that influence the pharmacodynamics and pharmacokinetics 
aspects of therapeutic medications [12]. With aging the fat/muscle ratio increases thus altering 
drug distribution, the gastrointestinal motility decreases causing longer transit time, the cardiac 
output and renal clearance decrease as well. In addition protein binding of drugs decreases thus 
increasing drug availability and senescence in the central nervous system associated with 
decreased resilience and increased side effects of medications [12]. 
1.2 The Scope of Comorbidities in SCD 
Comorbidity refers to unrelated pathologic or disease processes that occur concomitantly with 
SCD. Concomitant disorders can be pain or non-pain comorbidities [13]. They may have a 
negative, positive, or neutral effect on the primary basic sickling process. This is not unique to 
SCD pain and occurs frequently in other pain disorders. The comorbidities in SCD, however, are 
polymorbidity or multimorbidity because they encompass both pain and non-pain pathologic 
processes. 
 
As patients with SCD age, they become more at risk for developing comorbid conditions that 
were not previously seen or were rare in this patient population. For example, chronic pain, 
diabetes mellitus, obesity, and end-stage renal disease in SCD are seen more often now than in 
the 20th century. Cognizance of the complexity of SCD and its polymorbidities and the 
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implementation of preventative, educational, counseling, and prompt intervention measures may 
ameliorate the associated complexities of the disease and improve quality of life for its victims.  
 
Table 2 lists comorbidities that have been reported in SCD at least once. It includes only 
conditions that have an impact on sickle cell pain and hence, it may not be comprehensive. Most 
of the comorbidities listed in Table 2 can precipitate VOCs and may have a significant impact on 
the morbidity and mortality of patients. Details on selected comorbidities are described below 
and listed according to anatomic and/or pathophysiologic relevance. 
 
2. Acquired Immune Deficiency Syndrome 
Acquired immune deficiency syndrome may occur concomitantly in patients with SCD [14-19]. 
It is associated with several pain syndromes [20], but the types of pain syndromes that may arise 
when SCD and acquired immune deficiency syndrome coexist are not well characterized. At 
least in some patients, it appears that SCD may ameliorate the human immunodeficiency virus 
infection, due to host factors of which asplenia before infection may be one [15]. 
 
3. Anecdotal case reports of certain comorbidities 
Certain comorbidities of SCD were anecdotal in nature reported as case reports or mentioned in 
reviews. These include atrial fibrillation, Parkinson’s disease and irritable bowel syndrome [6, 
21]. Inflammatory bowel disease was also reported anecdotally in patients with SCD [22, 23]. 
Terry et al. [22] reported that the prevalence of proctocolitis in patients with SCD is 3 per 1000.  
 
4. Chronic Pulmonary Complications 
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These complications include asthma, chronic obstructive pulmonary disease (COPD), pulmonary 
restrictive (also known as fibrotic) lung disease, obstructive sleep apnea and pulmonary 
hypertension. The hallmark of these pulmonary complications is the presence of hypoxia and/or 
hypoxemia. Accordingly this set of complications could be due to SCD itself or comorbidities 
due to factors associated with the environment and aging. This dual causality may explain why 
these complications in SCD are not exactly the same as those in the general population as will be 
mentioned below. 
4.1 Asthma 
Asthma is a chronic inflammatory disorder characterized by repeated attacks of airway 
obstruction and symptoms of increased airway responsiveness [24]. It improves symptomatically 
in children and young adults but often it persists in adults and worsens with age. It is more 
common among children (20 – 70%) than adults (20 -30%) and is more common in African 
Americans [25]. It is associated with increased morbidity and mortality in people with sickle cell 
anemia [26, 27]. Its diagnosis is based on clinical picture and spirometry showing decreased 
forced expiratory volume in one second (FEV1).  
4.2 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic obstructive pulmonary disease is a common lung disease with two main types: chronic 
bronchitis and emphysema. The former type is the one that usually complicates SCD. It is 
characterized by airflow limitation that is not fully reversible but is usually progressive and 
associated with an abnormal inflammatory response to noxious particles or gases [28]. It is 
diagnosed by post-bronchodilator spirometry showing a reduction in the ratio of FEV1/FVC (< 
0.70). 
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4.3 Chronic Restrictive Lung Disease 
Chronic restrictive (also known as fibrotic) lung disease is characterized by persistent reduction 
in total lung capacity (TLC) with or without interstitial lung disease accompanied by a reduction 
in forced vital capacity (FVC) and functional residual capacity, but little change in residual 
volume. Diagnosed by spirometry showing FVC < 80% of predicted value or total lung capacity 
(TLC) < 90% of predicted value [29]. Patients with history of recurrent acute chest syndrome 
tend to have lower TLC consistent with pulmonary fibrosis/restrictive disease similar to the 
restrictive lung disease in patients without SCD [29].  
4.4 Obstructive Sleep Apnea 
Obstructive sleep apnea (OSA) is recurrent off (stopping) and on (restarting) breathing during 
sleep. It occurs when the muscles that support the soft tissues of the throat, such as the tongue 
and soft palate, temporarily relax and also when there is lymphoid proliferation. When these 
muscles relax, the airway is narrowed or closed, and breathing is momentarily cut off. Signs of 
OSA include snoring, morning headache, daytime sleepiness, etc. It is more common (about 4 
times) in children with SS than in controls. Treatment includes continuous positive airway 
pressure (CPAP) machine and surgery in severe cases [30, 31]. 
4.5 Pulmonary Hypertension 
Pulmonary hypertension is increased blood pressure in the pulmonary vasculature (both micro & 
macro vasculature). Clinical picture includes dyspnea, palpitations, pain (chest and abdomen), 
syncope, cyanosis, edema, fatigue and heart failure. The World Health Organization (WHO) 
classifies pulmonary hypertension into five groups as shown in Table 3. Among these the 
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pulmonary arterial hypertension (PAH) and the pulmonary venous hypertension (PVH) are the 
most common and most important in SCD.  
The pathophysiology of PAH includes two mechanisms: vascular obstruction and intimal 
hyperplasia. The vasoconstriction is due to decreased nitric oxide bioavailability and increased 
production of vaso-constrictors such as endothelin [32]. Intimal hyperplasia is the result of the 
hypoxia response pathway [33]. Specifically, hypoxia induced factors α and β (HIF-α and HIF-β) 
translocate to the nucleus across the cell membrane. The α/β complex activates the transcription 
of genes that increase cell proliferation and inflammation thus causing intimal hyperplasia and 
vaso-occlusion.  The PVH, on the other hand, is due to left ventricular failure. 
Pulmonary hypertension is technically defined by a mean pulmonary artery pressure (MPAP) ≥ 
25 mmHg which can be determined by echocardiography. In order to determine whether it is 
PAH or PVH, however, depends on the mean pulmonary capillary wedge pressure which cannot 
be determined by echocardiography but requires right heart catheterization (RHC). As shown in 
Table 4 PAH is characterized by MPAP ≥ 25 mmHg and capillary wedge pressure ≤ 15 mmHg 
whereas in PVH the capillary wedge pressure is > 15 mmHg. 
Treatment of pulmonary hypertension depends on its etiology. Thus the treatment of PVH targets 
the management of left ventricular failure. Treatment of PAH includes the use of vasodilators. 
This worked in PAH in the general population but not in PAH in patients with SCD. For now 
management of PAH in SCD includes blood transfusion and hydroxyurea. More studies and 
controlled trials are needed to determine the appropriate treatment of the PAH of SCD. 
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5. Fibromyalgia, Rheumatoid Arthritis and Osteoarthritis 
The signs and symptoms of these disorders overlap with those of SCD especially in the case of 
fibromyalgia [34]. The occurrence of fibromyalgia may be mistaken for sickle cell pain. 
Fibromyalgia pain is typically persistent, severe, and disabling and afflicts females 
approximately five times more often than males [35, 36]. In the United States, approximately 5 
to 6 million individuals suffer from fibromyalgia. The characteristic patient is a woman 20 to 45 
years of age who has diffuse chronic pain and chronic fatigue syndrome. Physical examination 
reveals no abnormalities, except for scattered tender points that are painful on palpation.  
Traditionally, the pain is subdivided into localized and diffuse. Interestingly, fibromyalgia is not 
an inflammatory disease, and primary central sensitization is thought to be the pathophysiologic 
mechanism of pain [37]. In one retrospective study [34], a rheumatologist reviewed the charts of 
nine patients with SCD and eleven inpatients with other forms of anemia and assessed them for 
fibromyalgia. Eight of nine patients with SCD fulfilled the classification criteria for 
fibromyalgia, compared to one of eleven patients without SCD (P < 0.001). Except for this 
retrospective chart review, fibromyalgia has not been reported in association with SCD. Again, 
its occurrence may be mistaken for sickle cell pain. Those patients with intractable chronic VOC 
pain may suffer from chronic fibromyalgia with superimposed acute VOCs. Such a possible 
combination needs further explanation and study. Thorough history, physical exam and 
radiological studies could differentiate rheumatoid arthritis and osteoarthritis from sickle cell 
pain. 
6. Gout 
The increased purine turnover of accelerated erythropoiesis in SS causes increased production 
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of uric acid [38] in amounts proportional to the severity of hemolysis. However, in most patients, 
increased production of uric acid is balanced by increased renal excretion [39, 40]. 
Consequently, most patients with SCD have a normal or moderately elevated serum uric acid 
level. Reports of clinical gout are infrequent [41-44] but usually involve the knees, wrists, and 
small finger joints rather than the big toe, as is typical of classical gout [45]. Gout may be 
underdiagnosed in a disease associated with recurrent joint pain and may be mistaken for the 
usual VOC of SCD. Hyperuricemia alone is not sufficient to establish diagnosis, which requires 
the demonstration of uric acid crystals in joint fluid [46, 47]. 
7. Hepatitis 
7.1 Viral Hepatitis 
The clinical, laboratory, and liver findings of patients with SS and viral hepatitis appear to be 
more complicated, more prolonged, and associated with significantly greater bilirubin levels than 
in control groups [45, 48]. Viral hepatitis occurs as frequently as in the general population [49]. 
Hepatitis C, and to a lesser extent hepatitis B, occur more often because of blood-product 
exposure. Improved blood-product testing has reduced the incidence of these infections, but they 
still occur. Patients with chronic hepatitis B or hepatitis C should be treated as any other patients. 
There has been some concern regarding the use of ribavirin because it may cause hemolytic 
anemia. If a patient on ribavirin develops worsening anemia, placing the patient on chronic 
transfusion would allow therapy to continue and would decrease sickle cell and anemia 
symptoms. A recent article reported good results in treating patients with SCD for chronic 
hepatitis C [50]. Liver transplant is as successful in patients with SCD as in other patients 
needing allograft liver transplant [51-54]. 
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7.2 Autoimmune Hepatitis 
Autoimmune hepatitis has been reported in patients with SCD [55-58]. Associated features of 
autoimmune hepatitis include rashes, skin ulcers, and joint disease. The etiology, natural course, 
and treatment of autoimmune hepatitis in SCD are unclear. If a patient has persistent liver 
symptoms and antibody titers to smooth muscles, a therapeutic trial of prednisone and 
azathioprine may be warranted. Referral to a hepatologist is indicated. 
8. Malignant Disorders 
8.1 Solid Tumors 
Solid tumors have been reported in patients with SCD including SS and hemoglobin (Hb) SC 
disease. Reported cancer included alveolar cell carcinoma [59], breast cancer [60-63], 
pheochromocytoma [64-66], renal medullary carcinoma [67, 68], testicular carcinoma, gastric 
cancer and poorly differentiated adenocarcinoma of unknown origin [63]. The age range of adult 
patients with solid tumors was 18 – 79 years with a mean age of 28.8 years. The mean age at 
death due to cancer, survival rate and the cancer incidence rate are not well defined due to the 
relatively small number of patients reported. In one institution the estimated cancer incidence 
rate was 1,74 per 1000 patient years and the mortality rate was 1.04 per 1000 patient years [63]. 
Renal medullary carcinoma was reported more often in sickle cell trait than in SCD [69-73].  
Surprisingly, colon cancer and gynecologic cancers (ovarian, cervical and endometrial) were not 
reported in SCD or the author could not find them.  
There is concern that long term use of hydroxyurea may be associated with increased incidence 
of malignancy. Moreover, the use of allogenic stem cell transplantation is on the increase and 
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this also is a risk factor for the development of cancer [74]. To date however, there is no 
evidence that either of these therapeutic approaches are associated with malignancy. 
8.2 Hematologic Malignancy 
Acute leukemia, chronic leukemia, Hodgkin and non-Hodgkin lymphoma have been reported in 
patients with SCD [75-78]. Hematologic malignancies tend to be more common in children than 
in adults with SCD with the exception of multiple myeloma. The combination of SCD and 
multiple myeloma is a bad combination. Both are characterized by hyperviscosity, renal failure, 
bone involvement, and sepsis, due to suppressed immunity [79-84].  
Unfortunately, the diagnosis of multiple myeloma may be missed initially since the presenting 
signs and symptom of multiple myeloma are often attributed to SCD. 
9. Obesity, Diabetes and Hypertension 
Obesity, diabetes and hypertension is a triad that is common in the general population at large in 
the USA. Obesity is the culprit of this triad that is associated with diabetes and hypertension. 
Obesity is a real epidemic in the US. About one third of the adult population in the US is obese 
(Figure 2).  Effective management of obesity prevents or ameliorates diabetes and hypertension.  
9.1 Definition of Obesity 
Obesity [85, 86] is best defined and diagnosed by the determination of the body mass index 
(BMI) which is equal to body weight in Kg divided by the square of height in meters [BMI = 
kg/m2 ]. The normal BMI is between 18.5 and 25. Classification of the BMI according to the 
WHO is shown in Table 5. BMI and survival are related [87, 88]. In addition to diabetes and 
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hypertension, other comorbidities associated with obesity include cardiovascular disease, sleep 
apnea, stroke and dementia [88, 89]. 
Obesity is on the rise in patients with SCD especially those with Hb SC disease. There are 
anecdotes of a few women aged 40-45 years with Hb SC disease whose BMI was > 40 [90]. The 
prevalence of overweight/obesity in patients with SCA or Hb SC disease is not well 
documented. Although resting energy expenditure in SCD is higher than in normal 
individuals which could protect or minimize overweight/obesity, the BMI of patients with 
SCD, especially with Hb SC disease seems to be following the same trend in the general 
population [91]. 
 
9.2 Management of obesity 
The US Preventive Services Task Force (USPSTF) recommends that providers screen all adults 
for obesity and to refer patients with BMI > 30 to multicomponent interventions (strong 
recommendation, moderate evidence). Dietary management entails the determination of the daily 
calorie requirement for each patient [92]. This includes the daily basal calorie requirement plus 
the additional requirement based on activity including exercise. The basal requirement depends 
on age, sex, height and weight and the requirement for activity depends whether it is mild 
moderate or extensive [21]. This is best determined by a nutritionist/physiologist. The patient, 
then, should keep record of the calorie intake so it does not exceed the daily requirement. The 
fact that all food items have labels listing the nutritional facts that include calories per serving, 
cholesterol, salt, etc. simplifies the dietary approach for the management of obesity. This 
approach, however, requires patient and adherence to the recommendations. 
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If dietary management fails, bariatric surgical treatment may be considered [93, 94]. The most 
frequently used surgical procedures for bariatric surgery include the Roux-en-Y gastric bypass 
and Sleeve Gastrectomy.  
 
 
Ophthalmological Comorbidities 
10.1 Cataract 
Cataract is progressive clouding of the lens of the eye resulting in blurred vision. It could be 
unilateral or bilateral. The word cataract is derived from the Latin cataracta meaning waterfall, 
cascade or white water. The simile indicates the difficulty to see clearly through waterfalls. 
Typically, cataract occur in older patients [6] and hence, are often referred to as senile cataracts. 
Cataracts in SCD were first reported in 1976 in two patients while receiving sodium cyanate for 
treatment of SS [95]. Ophthalmologic examination revealed bilateral posterior subcapsular 
cataracts in both patients. After discontinuation of cyanate therapy the lens opacities regressed in 
one of the patients. The first case of senile cataract was first reported in a 62-year-old man with 
SS [96]. His cataracts were also bilateral and posterior subcapsular. Cataract extraction from 
both eyes showed clear but thick, tenacious and mucoid aqueous humor unlike that seen in other 
senile cataracts without SCD. Like other ophthalmologic complications, cataracts seem to be 
more common in Hb SC disease than SS [97]. 
10.2 Glaucoma 
15 
 
The glaucoma reported in SCD is mostly secondary glaucoma [98-105]. Causes of secondary 
glaucoma include medications, trauma, physical injury, inflammation or eye surgery. In SCD, 
glaucoma is most often associated with traumatic hyphemas causing obstruction of the anterior 
chamber outflow tract. Less often, it may be associated with retinopathy. Glaucoma has been 
described in both SCD and sickle cell trait. 
In primary glaucoma the cause of obstruction of the aqueous humor flow is unknown. In older 
patients the aqueous humor flow may be less efficient leading to glaucoma. Anecdotally 
octogenarians with SCD and glaucoma have been described [6] but it is not known if their 
glaucoma is primary or secondary. 
10. Orofacial Comorbidities 
Certain complications and comorbidities of SCD have not been well studied. These include, 
among other systems, cranio-orbital, orofacial, dental and otologic complications. The 
prevalence, clinical manifestations, management and the association of these with other 
complication of SCD are poorly understood. The scanty data on these complications of SCD 
include observational studies and case reports. The highlights of these as they may pertain to 
older patients with SCD will be summarized in this review.   
11.1 Dental comorbidities 
Table 6 lists the dental comorbidities described in patients with SCD [106-113]. Caries are the 
most common dental comorbidity globally and in patients with SCD. Whether some of these 
complications are pathophysiologic manifestations of SCD or comorbidities in addition to SCD 
is controversial [114-116]. Some authors indicate that poor oral hygiene maintenance may be the 
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major cause of dental complications in SCD. Thus, it is imperative the dental follow-ups every 6 
months should be emphasized for patients with SCD. Aseptic necrosis of teeth has been 
described in some patients. The hallmark of this complication is the presence of dental pain in 
the absence of any dental pathology [117-119]. 
A recent Cochrane review of guidelines for the treatment of dental complications in SCD found 
that such guidelines are not available and unclear [112]. 
11.2 Temporomandibular Disorder 
A few patients with SCD have been reported with avascular necrosis of the temporomandibular 
joint [120-123]. This seems to be different from the classical temporomandibular disorder, or at 
least a rare cause of temporomandibular disorder. 
11. Otologic Comorbidities 
12.1 Deafness 
Hearing loss or deafness has been well described in patients with SCD. It is usually 
sensorineural in nature. It could be unilateral or bilateral with sudden or gradual onset. Possible 
etiologies include infection especially in children, tumors (neuroma or Schwannoma), 
labyrinthine hemorrhage or labyrinthitis ossificans [124-128]. 
Unlike the dental complications, three prospective, controlled, cross-sectional studies reported 
the effect of age on the prevalence of inner ear involvement. The first found mild sensory neural 
hearing loss (SNHL)  in three of 80 (3.8%) Nigerian children with SS 4 - 15 years old [129]. In 
the second study, the SNHL occurred in seven of 52 (13.5%) Nigerian children with SS 6 - 19 
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years old [130]. The third study was of 167 Nigerian adults 15 - 56 years of age with SS in 
whom the prevalence of SNHL was 66% [131]. Similarly, in a Brazilian prospective controlled 
study [132], the prevalence of SNHL in 28 adults with SS was 21.4% compared to 3.6% in 
control subjects (P = 0.05); moreover, the prevalence was greater among patients ≥ 25 years old 
than younger patients (P < aenso0.05). In Guadeloupe (France), the prevalence of SNHL was 
47.22% among patients with Hb SC disease and 43.5% among those with SS, and the majority of 
the patients had the Benin βs haplotype [133]. The prevalence in these countries is greater than 
what has been reported in the UK and US [134, 135]. Moreover, in Nigeria, Brazil, and 
Guadeloupe (France), the prevalence of SNHL was relatively high in control groups, albeit lower 
than that among patients with SCD; in comparison, the prevalence of SNHL in the control group 
of the UK study was nil. These findings suggest that the tropics may be a predisposing factor for 
SNHL, possibly as a malarial effect in some countries [135, 136]. SNHL is bilateral in most 
patients with SCD; when it is unilateral, it is more frequent on the left side. It seems to be more 
common in males and in patients with Hb SC disease [129, 131, 133-135, 137]. 
12.1 Tinnitus 
Tinnitus is the perception of sound in one or both ears the source of which is not external. It is 
often descried, among other things, as buzzing, ringing, humming, hissing, etc. It usually lasts 
for a relatively short period but it may recur on and off. In a few persons it may be prolonged. 
Tinnitus has been described in patients with SCD but always in the presence of deafness [132, 
134, 138]. 
12. Vaccination 
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The following vaccines are recommended for persons in the general population aged 60 years or 
older: 
1. Influenza vaccine annually 
2. Shingles (Herpes zoster ) vaccine once 
3. DPT (Diphtheria, pertussis and tetanus vaccine once even if taken before 
4. Anti-pneumococcal vaccines at least once, preferably every 5-7 years: 
a. PCV13 
b. PPSV23 
By analogy the same vaccines should be given to patients with SCD preferably once they reach 
the age of 50 years. To date, however, there are no specific recommendations for vaccinating 
older patients with SCD. 
13. Conclusion  
The advent of newborn screening, antibiotic prophylaxis, better vaccines, safer blood 
transfusion, iron chelation and hydroxyurea improved the survival of patients with SCD. This 
improvement, however, introduced a third dimension of SCD, namely the older and elderly 
patients with SCD. There is concern that the improved survival may be offset by the 
comorbidities of the older patients in the general population. Thus it is important that providers 
become aware of these comorbidities and how to differentiate them from the complications of 
the disease so that appropriate therapies can be given. 
Legend to Figures: 
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Figure 1: Life expectancy of patients with sickle cell disease from 1900 through 2010. The arrow 
indicates the infliction point where life expectancy of patients with sickle cell disease began to 
increase. Adapted from National Heart, Lung, and Blood Institute. Sickle cell research for 
treatment and cure (NIH Publication No. 02-5214). Bethesda, MD: US Department of Health and 
Human Services. 
 
Figure 2: This figure compares obesity rates from various countries. 
https://commons.wikimedia.org/wiki/File:Obesity_country_comparison_-_path.svg 
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